Blood MicroRNA Signatures Correlate With Hippocampal Volume and Atrophy Rates

The clinical management of Alzheimer's disease and related dementias is increasingly shifting toward a biological definition centered on measurable biomarkers of amyloid, tau, and neurodegeneration, a classification system known as the ATN framework [1]. While hippocampal atrophy remains a hallmark of cognitive decline and a critical surrogate marker for drug efficacy, its assessment currently relies on expensive and sometimes inaccessible neuroimaging [2, 3]. Meta-analysis data indicate that pharmacological interventions can influence these structural changes, as donepezil at a 10 mg dose significantly reduces hippocampal atrophy compared to placebo (standardized mean difference = 0.44, 95% CI [0.08 to 0.81], p = 0.01) [2]. The etiology of this tissue loss is multifactorial, involving interactions between metabolic factors like glycemic control and genetics, specifically the APOE ε4 allele, which can accelerate atrophy rates by over three times in amyloid-positive individuals [4, 5]. Consequently, there is an urgent clinical need for peripheral, minimally invasive tools, such as circulating microRNAs (small non-coding RNA sequences that regulate gene expression), that can detect early pathological shifts before irreversible tissue loss occurs [6, 7]. A recent study offers fresh insights into how these circulating molecular signals in the blood may reflect deep-seated structural changes in the brain, potentially providing a more accessible way to monitor neurodegeneration.